Clinical Trial Update: A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing post-phacoemulsification aqueous flare between ketorolac 0.45% BID and bromfenac 0.09% BID; results were completed and posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Inflammation Following Cataract Surgery

Drugs mentioned

• Bromfenac 0.09% ophthalmic solution (bromfenac)
• Ketorolac 0.45% ophthalmic solution (ketorolac tromethamine)

Snippet

Sponsor: Bucci Laser Vision Institute | Conditions: Post Operative Anterior Chamber Inflammation (Flare) | Phase 4 | Status: COMPLETED | Results posted: 2011-08-26